Search

Your search keyword '"Scalzulli, Emilia"' showing total 292 results
Start Over Author "Scalzulli, Emilia"
292 results on '"Scalzulli, Emilia"'

1. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib

Author

Mulas, Olga, Abruzzese, Elisabetta, Luciano, Luigiana, Iurlo, Alessandra, Attolico, Immacolata, Castagnetti, Fausto, Galimberti, Sara, Bonifacio, Massimiliano, Annunziata, Mario, Gozzini, Antonella, Orlandi, Ester Maria, Stagno, Fabio, Binotto, Gianni, Pregno, Patrizia, Fozza, Claudio, Loi, Maurizio, Trawinska, Malgorzata Monika, De Gregorio, Fiorenza, Cattaneo, Daniele, Albano, Francesco, Iezza, Miriam, Baratè, Claudia, Scaffidi, Luigi, Elena, Chiara, Giai, Valentina, Scalzulli, Emilia, Breccia, Massimo, La Nasa, Giorgio, and Caocci, Giovanni

Published
2024
Full Text
View/download PDF

5. Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

Author

Pepe, Sara, Rossi, Elena, Trawinska, Malgorzata, Tatarelli, Caterina, Di Veroli, Ambra, Maurillo, Luca, Romano, Atelda, Crescenzi, Sabrina Leonetti, di Toritto, Tommaso Caravita, Tafuri, Agostino, Latagliata, Roberto, Scalzulli, Emilia, Andriani, Alessandro, De Stefano, Valerio, and Breccia, Massimo

Published
2022
Full Text
View/download PDF

6. Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia.

Author

Costa, Alessandro, Gurnari, Carmelo, Scalzulli, Emilia, Cicconi, Laura, Guarnera, Luca, Carmosino, Ida, Cerretti, Raffaella, Bisegna, Maria Laura, Capria, Saveria, Minotti, Clara, Iori, Anna Paola, Torrieri, Lorenzo, Venditti, Adriano, Pulsoni, Alessandro, Martelli, Maurizio, Voso, Maria Teresa, and Breccia, Massimo

Subjects
TREATMENT of acute promyelocytic leukemia, HEMATOPOIETIC stem cell transplantation, PATIENTS, TRANSPLANTATION of organs, tissues, etc., ACUTE promyelocytic leukemia, SALVAGE therapy, TREATMENT effectiveness, RETROSPECTIVE studies, CANCER patients, MULTIVARIATE analysis, ARSENIC compounds, MEDICAL records, ACQUISITION of data, OXIDES, TRETINOIN, STATISTICS, DISEASE relapse, OVERALL survival
Abstract

Simple Summary: Relapses of acute promyelocytic leukemia (APL) remain a challenge despite the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Given the variability in salvage therapies and emerging evidence supporting the deferral of hematopoietic cell transplantation (HCT) in patients receiving ATO, we analyzed the outcomes of a multicentric cohort of 67 relapsed APL patients. Better outcomes were reported with ATO ± ATRA compared to chemo-based regimens and ATRA ± Gemtuzumab ozogamicin (GO). A significant survival advantage was observed for patients undergoing HCT in the chemo-based cohort (p = 0.017), but not in the ATO-based group (p = 0.12). Achieving molecular complete remission (CR) post salvage therapy emerged as the main prognostic factor for second relapses in both univariate and multivariate analyses. Our findings support the efficacy of ATO-based therapies in first relapse and enhance the role of molecular remission as an independent outcome predictor in both first and second APL relapses. Background: The introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has radically improved the prognosis of acute promyelocytic leukemia (APL), with cure rates above 80%. While relapse occurs in less than 20% of cases, addressing this issue remains challenging. Identifying effective salvage therapies for relapsed APL is crucial to improve patient outcomes. Methods: A retrospective analysis was performed on a multicentric cohort of 67 APL patients in first relapse, treated in three Italian hematology centers from June 1981 to November 2021. The overall survival (OS) and cumulative incidence of relapse (CIR) were calculated, and predictive factors were assessed using Cox regression models. Results: Overall, 61 patients (91%) received ATO ± ATRA (40.3%), chemo-based regimens (40.3%), or ATRA ± Gemtuzumab ozogamicin (GO) (10.4%). Complete remission (CR) was achieved in 98.2% of patients (molecular CR, n = 71.4%). With a median follow-up time of 54.5 months, the 5-year OS was 73% in the ATO ± ATRA group, 44% in the chemo-based group, and 29% in the ATRA ± GO group (p = 0.035). The 5-year OS rate was also higher for transplant recipients vs. non-recipients within the chemo-based cohort (50% vs. 33%, p = 0.017), but not in the ATO-based cohort (p = 0.12). ATO-based salvage therapy resulted in better OS in both univariate (p = 0.025) and multivariate analyses (p = 0.026). The 2-year CIR was higher in patients without molecular CR vs. patients in molecular CR (66% vs. 24%, p = 0.034). Molecular CR was a significant predictor of second relapse in both univariate (p = 0.035) and multivariate analyses (p = 0.036). Conclusions: Our findings support the efficacy of ATO-based therapies in first relapse of APL and confirm the achievement of molecular remission as an independent outcome predictor in both first and second APL relapse. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

Author

Gurnari, Carmelo, Piciocchi, Alfonso, Soddu, Stefano, Bonanni, Fabrizio, Scalzulli, Emilia, Niscola, Pasquale, Di Veroli, Ambra, Piccioni, Anna Lina, Piedimonte, Monica, Maiorana, Gianluca, Salutari, Prassede, Cicconi, Laura, Santopietro, Michelina, Gumenyuk, Svitlana, Sarlo, Chiara, Fenu, Susanna, Tafuri, Agostino, Latagliata, Roberto, Fianchi, Luana, Criscuolo, Marianna, Maciejewski, Jaroslaw P., Maurillo, Luca, Buccisano, Francesco, Breccia, Massimo, and Voso, Maria Teresa

Published
2022
Full Text
View/download PDF

9. Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib

Author

Caocci, Giovanni, Mulas, Olga, Capodanno, Isabella, Bonifacio, Massimiliano, Annunziata, Mario, Galimberti, Sara, Luciano, Luigiana, Tiribelli, Mario, Martino, Bruno, Castagnetti, Fausto, Binotto, Gianni, Pregno, Patrizia, Stagno, Fabio, Abruzzese, Elisabetta, Bocchia, Monica, Gozzini, Antonella, Albano, Francesco, Fozza, Claudio, Luzi, Debora, Efficace, Fabio, Simula, Maria Pina, Scaffidi, Luigi, Baratè, Claudia, De Gregorio, Fiorenza, Stella, Rossella, Gugliotta, Gabriele, Pirillo, Francesca, Trawinska, Malgorzata Monika, Sicuranza, Anna, Cattaneo, Daniele, Attolico, Immacolata, Scalzulli, Emilia, Iurlo, Alessandra, Foà, Robin, Breccia, Massimo, and La Nasa, Giorgio

Published
2021
Full Text
View/download PDF

11. Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety

Author

Laganà, Alessandro, Scalzulli, Emilia, Bisegna, Maria Laura, Carmosino, Ida, Ielo, Claudia, Costa, Alessandro, Torrieri, Lorenzo, Totaro, Matteo, Martelli, Maurizio, and Breccia, Massimo

Abstract

ABSTRACTIntroductionChronic myeloid leukemia (CML) prevalence is currently increasing due to the great efficacy of tyrosine kinase inhibitor (TKI) therapy. Discontinuation of treatment in the long-term, owing to avoid off-target side effects or treatment-free remission (TFR), has become an additional treatment goal in CML patients who achieved a deep molecular response (DMR). Second-generation TKIs (2 G-TKIs) have a significantly higher rate of DMR than imatinib. Hence, especially in young patients with a strategy of TFR, 2 G-TKIs are becoming the most frequently used TKIs and may increase TFR attempts in the future.Areas coveredIn this review, the main findings extrapolated from clinical trials and real-life evidence regarding 2 G-TKIs discontinuation were discussed, through broad research on Medline, Embase, and archives from EHA and ASH congresses.Expert opinionOverall, TFR rate after 2 G-TKIs is ranging from 40% to 60% for selected patients with sustained DMR and it can be considered a safe procedure, that have become, nowadays, a daily practice. However, many crucial aspects regarding treatment choices, timings, as well as predictive factors, patient communication, and optimal strategies need to be better clarified to improve successful TFR rate.

Published
2024
Full Text
View/download PDF

14. Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation.

Author

Laganà, Alessandro, Passucci, Mauro, Pepe, Sara, Scalzulli, Emilia, Carmosino, Ida, Costa, Alessandro, Bisegna, Maria Laura, Ielo, Claudia, Martelli, Maurizio, and Breccia, Massimo

Subjects
MYELOFIBROSIS, NEUTROPHIL lymphocyte ratio, PROGRESSION-free survival, PROGNOSIS, RUXOLITINIB, SYMPTOM burden
Abstract

Background: Myelofibrosis (MF) is a clonal Philadelphia chromosome negative myeloproliferative neoplasm (Ph‐MPN). MF is featured by an inflammatory condition that can also drive the progression of disease. Ruxolitinib (ruxo) is the‐first‐in‐class Jak1/2 inhibitor approved for treatment of MF, proved to reduce spleen volume and decrease symptom burden. In various malignancies neutrophil‐to‐lymphocyte ratio (NLR) has been indicated as predictor of progression free survival (PFS) and overall survival (OS). NLR might reflect the balance between systemic inflammation and immunity and is emerging as a prognostic biomarker in several neoplasms, including the hematological ones. Methods: We analyzed a cohort of 140 MF patients treated with ruxo to validate baseline NLR (as a continuous variable and as a cut‐off 2) as predictor of OS and of ruxo treatment discontinuation. Results: We found that both baseline NLR as a continuous variable [HR 0.8 (95% CI: 0.7–0.9) (p =.006)] and NLR (<2 vs. ≥2) [HR 3.4 (95% CI: 1.6–7.0) (p =.001)] were significantly associated with OS. Censoring for patients undergone allotransplant, baseline NLR <2 was predictive of an earlier ruxo any‐other‐cause discontinuation [HR 3.7 (95%CI 1.7–8.3) (p <.001)]. Conclusions: NLR before starting ruxo treatment may be used as a simple and early predictor of OS and earlier ruxo discontinuation in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

Author

Marcé, Sílvia, primary, Méndez, Aleix, additional, Xicoy, Blanca, additional, Estrada, Natalia, additional, Cabezón, Marta, additional, Sturla, Antonella Luciana, additional, García, Miriam Ratia, additional, Angona, Anna, additional, Amat, Paula, additional, Escribano Serrat, Silvia, additional, Scalzulli, Emilia, additional, Morgades, Mireia, additional, Senín, Alicia, additional, Hernández-Boluda, Juan Carlos, additional, Ferrer-Marín, Francisca, additional, Anguita, Eduardo, additional, Cortés, Montserrat, additional, Plensa, Esther, additional, Breccia, Massimo, additional, García-Gutierrez, Valentín, additional, and Zamora, Lurdes, additional

Published
2024
Full Text
View/download PDF

17. Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report

Author

Ligia, Silvio, primary, Scalzulli, Emilia, additional, Carmosino, Ida, additional, Palumbo, Giovanna, additional, Molinari, Maria Chiara, additional, Poggiali, Rebecca, additional, Costa, Alessandro, additional, Bisegna, Maria Laura, additional, Martelli, Maurizio, additional, and Breccia, Massimo, additional

Published
2024
Full Text
View/download PDF

20. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib

Author

Mulas, Olga, primary, Abruzzese, Elisabetta, additional, Luciano, Luigiana, additional, Iurlo, Alessandra, additional, Attolico, Immacolata, additional, Castagnetti, Fausto, additional, Galimberti, Sara, additional, Bonifacio, Massimiliano, additional, Annunziata, Mario, additional, Gozzini, Antonella, additional, Orlandi, Ester Maria, additional, Stagno, Fabio, additional, Binotto, Gianni, additional, Pregno, Patrizia, additional, Fozza, Claudio, additional, Loi, Maurizio, additional, Trawinska, Malgorzata Monika, additional, De Gregorio, Fiorenza, additional, Cattaneo, Daniele, additional, Albano, Francesco, additional, Iezza, Miriam, additional, Baratè, Claudia, additional, Scaffidi, Luigi, additional, Elena, Chiara, additional, Giai, Valentina, additional, Scalzulli, Emilia, additional, Breccia, Massimo, additional, La Nasa, Giorgio, additional, and Caocci, Giovanni, additional

Published
2023
Full Text
View/download PDF

24. Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors

Author

Mulas, Olga, Caocci, Giovanni, Stagno, Fabio, Bonifacio, Massimiliano, Annunziata, Mario, Luciano, Luigiana, Orlandi, Ester Maria, Abruzzese, Elisabetta, Sgherza, Nicola, Martino, Bruno, Albano, Francesco, Galimberti, Sara, Pregno, Patrizia, Bocchia, Monica, Castagnetti, Fausto, Tiribelli, Mario, Binotto, Gianni, Gozzini, Antonella, Capodanno, Isabella, Fozza, Claudio, Luzi, Debora, Efficace, Fabio, Simula, Maria Pina, Scaffidi, Luigi, De Gregorio, Fiorenza, Elena, Chiara, Trawinska, Malgorzata Monika, Cattaneo, Daniele, Attolico, Imma, Baratè, Claudia, Pirillo, Francesca, Sicuranza, Anna, Gugliotta, Gabriele, Stella, Rossella, Scalzulli, Emilia, Iurlo, Alessandra, Foà, Robin, Breccia, Massimo, and La Nasa, Giorgio

Published
2020
Full Text
View/download PDF

25. Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort.

Author

Costa, Alessandro, Carmosino, Ida, Scalzulli, Emilia, Minotti, Clara, De Propris, Maria Stefania, Masucci, Chiara, Passucci, Mauro, Bisegna, Maria Laura, Ielo, Claudia, Pepe, Sara, Diverio, Daniela, Martelli, Maurizio, and Breccia, Massimo

Subjects
ACUTE promyelocytic leukemia, DISEASE risk factors, EARLY death, GASTROINTESTINAL hemorrhage, PLATELET count, RETROSPECTIVE studies, PRELEUKEMIA, CD34 antigen
Abstract

This article discusses the risk of early death (ED) in patients with acute promyelocytic leukemia (APL). The study found that the mortality rate was significantly higher in high-risk and very high-risk patients compared to low-risk patients. The analysis did not reveal any differences in bone marrow morphology or cytometric markers between ED and non-ED patients, suggesting that these factors may not play a role in determining the risk of early mortality. The study also evaluated the effectiveness of the ED risk score in patients treated with the ATO+ATRA regimen and found no premature deaths in this group. The article concludes that the ED risk score is effective in predicting early mortality and emphasizes the importance of timely diagnosis and treatment in improving outcomes for APL patients. [Extracted from the article]

Published
2024
Full Text
View/download PDF

27. One‐month qRT‐PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission

Author

Laganà, Alessandro, primary, Pepe, Sara, additional, Scalzulli, Emilia, additional, Carmosino, Ida, additional, Passucci, Mauro, additional, Ielo, Claudia, additional, Costa, Alessandro, additional, Masucci, Chiara, additional, Diverio, Daniela, additional, Martelli, Maurizio, additional, and Breccia, Massimo, additional

Published
2023
Full Text
View/download PDF

28. Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents

Author

Scamuffa, Maria Cristina, primary, Latagliata, Roberto, additional, Carmosino, Ida, additional, Di Veroli, Ambra, additional, Scalzulli, Emilia, additional, Trapè, Giulio, additional, Ciotti, Giulia, additional, De Angelis, Gioia, additional, Tartaglia, Germana, additional, Tarnani, Michela, additional, Breccia, Massimo, additional, and Girmenia, Corrado, additional

Published
2023
Full Text
View/download PDF

29. PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI

Author

Torra, Silvia Marce, primary, Méndez, Aleix, additional, Sturla, Antonella Luciana, additional, Ratia, Miriam, additional, Figueras, Anna Angona, additional, Amat, Paula, additional, Ferrer-Marín, Francisca, additional, Escribano, Silvia, additional, Scalzulli, Emilia, additional, Sansa, Montserrat Cortes, additional, Plensa, Esther, additional, Estrada, Natalia, additional, Marco, Marta Cabezon, additional, Morgades, Mireia, additional, Magan, Maria Alicia Senin, additional, Hernandez-Boluda, Juan Carlos, additional, Anguita, Eduardo, additional, Breccia, Massimo, additional, García-Gutiérrez, Valentín, additional, Cirici, Blanca Xicoy, additional, and Zamora, Lurdes, additional

Published
2023
Full Text
View/download PDF

30. Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

Author

Breccia, Massimo, Luciano, Luigiana, Pugliese, Novella, Rossi, Elena, Tiribelli, Mario, Scalzulli, Emilia, Bonifacio, Massimiliano, Martino, Bruno, Latagliata, Roberto, Benevolo, Giulia, Caocci, Giovanni, Binotto, Gianni, Martinelli, Vincenzo, Cavo, Michele, Pane, Fabrizio, De Stefano, Valerio, Foà, Robin, and Palandri, Francesca

Published
2019
Full Text
View/download PDF

33. Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic‐phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML

Author

Tiribelli, Mario, primary, Latagliata, Roberto, additional, Breccia, Massimo, additional, Capodanno, Isabella, additional, Miggiano, Maria Cristina, additional, Cavazzini, Francesco, additional, Bucelli, Cristina, additional, Attolico, Immacolata, additional, Crescenzi, Sabrina Leonetti, additional, Russo, Sabina, additional, Annunziata, Mario, additional, Sorà, Federica, additional, Bonifacio, Massimiliano, additional, Mulas, Olga, additional, Loglisci, Giuseppina, additional, Maggi, Alessandro, additional, Binotto, Gianni, additional, Crisà, Elena, additional, Scortechini, Anna Rita, additional, Leporace, Anna Paola, additional, Sancetta, Rosaria, additional, Murgano, Pamela, additional, Abruzzese, Elisabetta, additional, Stagno, Fabio, additional, Rapezzi, Davide, additional, Luzi, Debora, additional, Vincelli, Iolanda, additional, Bocchia, Monica, additional, Fava, Carmen, additional, Malato, Alessandra, additional, Crugnola, Monica, additional, Pizzuti, Michele, additional, Lunghi, Francesca, additional, Galimberti, Sara, additional, Dalmazzo, Matteo, additional, Fanin, Renato, additional, Scalzulli, Emilia, additional, Foà, Robin, additional, Iurlo, Alessandra, additional, Saglio, Giuseppe, additional, and Specchia, Giorgina, additional

Published
2023
Full Text
View/download PDF

35. Case Report: Infectious prophylaxis in hematological malignancies

Author

Passucci, Mauro, primary, Masucci, Chiara, additional, Paoletti, Francesca, additional, Ielo, Claudia, additional, Costa, Alessandro, additional, Carmosino, Ida, additional, Scalzulli, Emilia, additional, Martelli, Maurizio, additional, Gentile, Giuseppe, additional, and Breccia, Massimo, additional

Published
2023
Full Text
View/download PDF

36. Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

Author

Caocci, Giovanni, Mulas, Olga, Capodanno, Isabella, Abruzzese, Elisabetta, Iurlo, Alessandra, Luciano, Luigiana, Albano, Francesco, Annunziata, Mario, Tiribelli, Mario, Bonifacio, Massimiliano, Galimberti, Sara, Castagnetti, Fausto, Sgherza, Nicola, Stagno, Fabio, Gozzini, Antonella, Orlandi, Ester Maria, Luzi, Debora, Binotto, Gianni, Pregno, Patrizia, Fozza, Claudio, Efficace, Fabio, Simula, Maria Pina, Trawinska, Malgorzata Monika, Cattaneo, Daniele, De Gregorio, Fiorenza, Attolico, Immacolata, Stella, Rossella, Scaffidi, Luigi, Baratè, Claudia, Gugliotta, Gabriele, Scalzulli, Emilia, Elena, Chiara, Pirillo, Francesca, Foà, Robin, Breccia, Massimo, and Nasa, Giorgio La

Published
2020
Full Text
View/download PDF

38. Acute leukemia diagnosis during the COVID-19 pandemic

Author

GUARNERA, Luca, primary, BUZZATTI, Elisa, additional, MARCHESI, Francesco, additional, ARMIENTO, Daniele, additional, MAZZONE, Carla, additional, CAPRIA, Saveria, additional, SCALZULLI, Emilia, additional, MALFONA, Francesco, additional, CHIARETTI, Sabina, additional, PALMIERI, Raffaele, additional, PATERNO, Giovangiacinto, additional, FRANZESE, Chiara, additional, BONANNI, Fabrizio, additional, SAVI, Arianna, additional, PASQUALONE, Gianmario, additional, MORETTI, Federico, additional, MAURILLO, Luca, additional, BUCCISANO, Francesco, additional, VENDITTI, Adriano, additional, and DEL PRINCIPE, Maria Ilaria, additional

Published
2023
Full Text
View/download PDF

39. Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases

Author

Andriani, Alessandro, primary, Breccia, Massimo, additional, Scalzulli, Emilia, additional, Cerchiara, Elisabetta, additional, Romano, Atelda, additional, Biagi, Annalisa, additional, Maurillo, Luca, additional, Trawinska, Malgorzata Monika, additional, Paciaroni, Katia, additional, Santopietro, Michelina, additional, Leonetti Crescenzi, Sabrina, additional, D'Addosio, Ada, additional, Tatarelli, Caterina, additional, Abruzzese, Elisabetta, additional, Di Veroli, Ambra, additional, Rossi, Elena, additional, Latagliata, Roberto, additional, and Montanaro, Marco, additional

Published
2022
Full Text
View/download PDF

40. Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Author

Capodanno, Isabella, primary, Tiribelli, Mario, additional, Miggiano, Maria Cristina, additional, Bucelli, Cristina, additional, Cavazzini, Francesco, additional, Leonetti Crescenzi, Sabrina, additional, Russo, Sabina, additional, Scalzulli, Emilia, additional, Bernardelli, Andrea, additional, Luciano, Luigiana, additional, Mulas, Olga, additional, Loglisci, Giuseppina, additional, Elena, Chiara, additional, Pizzano, Umberto, additional, Attolico, Immacolata, additional, Binotto, Gianni, additional, Crisà, Elena, additional, Sportoletti, Paolo, additional, Di Veroli, Ambra, additional, Scortechini, Anna Rita, additional, Leporace, Annapaola, additional, Basile, Maria, additional, Crugnola, Monica, additional, Stagno, Fabio, additional, Murgano, Pamela, additional, Rapezzi, Davide, additional, Luzi, Debora, additional, Iurlo, Alessandra, additional, Bocchia, Monica, additional, Fava, Carmen, additional, Malato, Alessandra, additional, Galimberti, Sara, additional, Vincelli, Iolanda Donatella, additional, Trawinska, Malgorzata Monika, additional, Pizzuti, Michele, additional, Caocci, Giovanni, additional, Bonifacio, Massimiliano, additional, Saglio, Giuseppe, additional, Specchia, Giorgina, additional, Breccia, Massimo, additional, and Latagliata, Roberto, additional

Published
2022
Full Text
View/download PDF

43. Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation

Author

Puzzolo, Maria Cristina, primary, Breccia, Massimo, additional, Mariglia, Paola, additional, Colafigli, Gioia, additional, Pepe, Sara, additional, Scalzulli, Emilia, additional, Mariggiò, Elena, additional, Latagliata, Roberto, additional, Guarini, Anna, additional, and Foà, Robin, additional

Published
2022
Full Text
View/download PDF

46. Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination.

Author

Masucci, Chiara, Passucci, Mauro, Scalzulli, Emilia, Carmosino, Ida, Capriata, Marcello, Costa, Alessandro, Ielo, Claudia, Martelli, Maurizio, and Breccia, Massimo

Subjects
MERKEL cell carcinoma, POLYCYTHEMIA vera, RUXOLITINIB, SKIN cancer, SECONDARY primary cancer, BLOOD diseases
Abstract

We describe a case of second primary malignancy in a 65-year-old patient affected by polycythemia vera treated with the JAK 1/2 inhibitor ruxolitinib. The latter is recognized as a risk factor for the onset of non-melanoma skin cancers in many retrospective and perspective studies, but the concomitant use of ruxolitinib with new immunotherapies is very rarely reported, and the safety of this association is still not clear. In our case, ruxolitinib combined with the anti-PD-L1 avelumab demonstrated both safety and efficacy for hematological disease control and underlying carcinoma remission. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group

Author

Breccia, Massimo, primary, Petriccione, Luca, additional, Tatarelli, Caterina, additional, De Muro, Marianna, additional, Trawinska, Malgorzata Monica, additional, Santopietro, Michelina, additional, Spadea, Antonio, additional, Di Veroli, Ambra, additional, Scalzulli, Emilia, additional, Paciaroni, Katia, additional, Tafuri, Agostino, additional, Latagliata, Roberto, additional, Andriani, Alessandro, additional, and Di Napoli, Arianna, additional

Published
2022
Full Text
View/download PDF

48. Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?

Author

Campagna, Alessia, primary, De Benedittis, Daniela, additional, Fianchi, Luana, additional, Scalzulli, Emilia, additional, Rizzo, Lorenzo, additional, Niscola, Pasquale, additional, Piccioni, Anna Lina, additional, Di Veroli, Ambra, additional, Mancini, Stefano, additional, Villivà, Nicoletta, additional, Martini, Tiziano, additional, Mohamed, Sara, additional, Carmosino, Ida, additional, Criscuolo, Marianna, additional, Fenu, Susanna, additional, Aloe Spiriti, Maria Antonietta, additional, Buccisano, Francesco, additional, Mancini, Marco, additional, Tafuri, Agostino, additional, Breccia, Massimo, additional, Poloni, Antonella, additional, and Latagliata, Roberto, additional

Published
2022
Full Text
View/download PDF

49. CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases.

Author

Iaquinta, Giovanni, Scalzulli, Emilia, Angeloni, Silvia, Carmosino, Ida, Costa, Alessandro, Ielo, Claudia, Passucci, Mauro, Masucci, Chiara, Martelli, Maurizio, Grammatico, Paola, and Breccia, Massimo

Subjects
*CHRONIC myeloid leukemia, *MYELOPROLIFERATIVE neoplasms, *CHRONIC leukemia
Abstract

Atypical chronic myeloid leukemia (aCML) is a rare MDS/MPN disease characterized by the absence of BCR::ABL1 rearrangement and well known typical mutations associated with myeloproliferative disorders. Mutational landscape associated with this disease was recently described with frequent involvement of SETBP1 and ETNK1 mutations. CCND2 mutations have not been frequently detected in MPN or MDS/MPN patients. We describe two cases of aCML with two CCND2 mutations in 280 and 281 codons which rapidly develop progressive characteristics, and we reviewed the literature about this unfavorable association, suggesting a role as a new possible marker of aggressive disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results